Panadiplon

Source: Wikipedia, the free encyclopedia.
Panadiplon
Clinical data
ATC code
  • none
Legal status
Legal status
  • See
    Hepatotoxic
Identifiers
  • 3-(5-cyclopropyl-1,2,4-oxadiazol-3-yl)-5 -propan-2-ylimidazo[5,1-c]quinoxalin-4-one
JSmol)
  • O=C4N(c5ccccc5n3cnc(c1nc(on1)C2CC2)c34)C(C)C
  • InChI=1S/C18H17N5O2/c1-10(2)23-13-6-4-3-5-12(13)22-9-19-14(15(22)18(23)24)16-20-17(25-21-16)11-7-8-11/h3-6,9-11H,7-8H2,1-2H3 checkY
  • Key:ZGEGOFCLSWVVKG-UHFFFAOYSA-N checkY
 ☒NcheckY (what is this?)  (verify)

Panadiplon (U-78875) is an

amnestic effect, and so is classified as a nonbenzodiazepine anxiolytic.[1]

Panadiplon acts as a high-affinity GABAA receptor partial agonist,[2][3] but despite showing a useful effects profile of a potent anxiolytic with little sedative effects, panadiplon was discontinued from clinical development for use in humans after showing evidence of liver damage in both animals and human trials.[4][5] Panadiplon however continues to be used in animal research, mainly as a subtype-selective reference drug to compare other GABAA agonists against.[6][7]

References

  1. PMID 1681085
    .
  2. PMID 10336537
    .
  3. PMID 11164687
    .
  4. PMID 7740546
    .
  5. PMID 11336974
    .
  6. S2CID 97681615
    .
  7. S2CID 23880756
    .
Retrieved from "https://en.wikipedia.org/w/index.php?title=Panadiplon&oldid=1121387323"